8 days accumulation .
The project entered the market this year.
The price is near the buyer's support.
price is formed in the form of the first wave of growth.
First Wave BioPharma is a clinical-stage biopharmaceutical company that specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases.
52 Week Range 1.27 - 26.30
Now the price is close to all time low and looks like a buy opportunity!
James Sapirstein
Chairman, President and CEO of First Wave BioPharma, Inc.:
"We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative...
